Nachrichten zur Gilead Sciences Inc. Aktie

Gilead to Report Q3 Earnings: How Should You Play the Stock Now?

Gilead Sciences heads into Q3 earnings with strong HIV sales, Yeztugo momentum and expanding oncology prospects, but competitive pressures warrant…

Whats in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?

Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q326 results.…

Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note

Gilead Sciences (GILD) concluded the recent trading session at $153.57, signifying a -1.88% move from its prior days close.…

Gilead Sciences (GILD) Rises Higher Than Market: Key Facts

Gilead Sciences (GILD) closed the most recent trading day at $157.48, moving +2.57% from the previous trading session.…

Can Gileads Deal With VIR Boost Its Oncology Pipeline and Growth?

Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting…

Gilead Sciences (GILD) Laps the Stock Market: Heres Why

Gilead Sciences (GILD) closed the most recent trading day at $151.17, moving +2.77% from the previous trading session.…

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $144.74, moving 1.87% from the previous trading session.…

Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors

In the latest trading session, Gilead Sciences (GILD) closed at $149.45, marking a -1.21% move from the previous day.…

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.42, denoting a +1.88% move from the…

Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?

Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies.…

COCP: $5 Million Private Placement with OPKO Health

By David Bautz, PhDNASDAQ: COCPREAD THE FULL COCP RESEARCH REPORTBusiness UpdateCDI-988 Approaches Key ReadoutCocrystal Pharma, Inc. (NASDAQ: COCP) is continuing…

Gilead yanks out a thorn in its side in major court ruling

A federal appeals court just handed Gilead Sciences (GILD) a legal win that extends into the companys revenue. The decision…

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on…

Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)

…

Key HIV stat over 70% leaves BofA siding with Gilead

Gilead Sciences (GILD) closed a strong second quarter, and Wall Street noticed. The drugmaker beat sales expectations across its biggest…

Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates

Gilead (GILD) delivered earnings and revenue surprises of +4.53% and +5.92%, respectively, for the quarter ended June 2026. Do the…

Gilead Sciences Aktie vor Q2 2026 Zahlen: 180 oder 120 USD? Analysten-Kursziele und Ratings

Bad Marienberg (www.aktiencheck.de) - Welche Kursziele und Ratings trauen die Analysten der führenden Banken und Research-Häuser der Aktie des biopharmazeutischen…

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $129.31, moving 1.18% from the previous trading session.…

Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the most recent trading session, Gilead Sciences (GILD) closed at $134.28, indicating a -1.48% shift from the previous trading…

Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $129.83, denoting a -3.72% move from the…

Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $123.84, denoting a -1.05% move from the…

The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK

Gilead Sciences won FDA acceptance for a filing that could expand Yeztugo into a once-weekly oral HIV prevention option, broadening…

Gilead Sciences, Inc. (GILD) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

…

Stronger HIV Pipeline And Acquisition Charges Might Change The Case For Investing In Gilead Sciences (GILD)

In early May 2026, Gilead Sciences reported first-quarter 2026 results showing revenue of US$6.96 billion and net income of US$2.02…

Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?

Gilead Sciences gears up for Q1 earnings with HIV drugs driving growth, but cell therapy headwinds and rising costs could…

Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know

Gilead Sciences (GILD) closed at $130.84 in the latest trading session, marking a +1.55% move from the prior day.…

Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts

Gilead Sciences (GILD) reached $130.4 at the closing of the latest trading day, reflecting a -2.42% change compared to its…

Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?

BMY stands out vs GILD, supported by a cheaper valuation, strong growth portfolio, and improving earnings outlook despite generic headwinds.…

Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $135.87, denoting a -1.29% move from the…

Heres Why Gilead Sciences (GILD) Gained But Lagged the Market Today

In the most recent trading session, Gilead Sciences (GILD) closed at $140.45, indicating a +1.02% shift from the previous trading…

Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline Expansion Transcript

…

dpa-AFX ProFeed